Knox A J, Tattersfield A E, Britton J R
Respiratory Medicine Unit, City Hospital, Nottingham.
Br J Clin Pharmacol. 1988 Jun;25(6):758-60. doi: 10.1111/j.1365-2125.1988.tb05264.x.
To determine the role of Na/K ATPase in determining bronchial reactivity in man, we studied the effect of 1 mg inhaled ouabain on histamine reactivity in six normal and 10 asthmatic subjects in a placebo controlled, crossover study. sGaw was measured before and up to 2 h after drug, followed by a histamine challenge test to estimate the dose of histamine causing a 35% reduction in sGAW (PD35). sGAW values after ouabain and placebo did not differ significantly. Ouabain did not affect bronchial reactivity, geometric mean (95% CI) PD35 histamine values following ouabain and placebo were 8.98 (3.8-21.2) and 7.75 (3.2-18.7) mumol respectively in normal subjects and 0.46 (0.18-1.21) and 0.69 (0.22-2.13) in asthmatic subjects. We were thus unable to demonstrate a role for Na/K ATPase in determining bronchial reactivity to histamine in man.
为了确定钠钾ATP酶在人体支气管反应性中的作用，我们在一项安慰剂对照的交叉研究中，研究了吸入1毫克哇巴因对6名正常人和10名哮喘患者组胺反应性的影响。在用药前及用药后2小时内测量比气道传导率（sGaw），随后进行组胺激发试验，以估计使sGAW降低35%的组胺剂量（PD35）。哇巴因和安慰剂后的sGAW值无显著差异。哇巴因不影响支气管反应性，正常受试者在使用哇巴因和安慰剂后的组胺PD35几何均值（95%可信区间）分别为8.98（3.8 - 21.2）和7.75（3.2 - 18.7）微摩尔，哮喘患者分别为0.46（0.18 - 1.21）和0.69（0.22 - 2.13）。因此，我们无法证明钠钾ATP酶在人体支气管对组胺的反应性中起作用。
